Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 15, 2019 5:30pm
119 Views
Post# 29829367

RE:RE:RE:RE:RE:RE:Theralase Technologies as yet undiscovered

RE:RE:RE:RE:RE:RE:Theralase Technologies as yet undiscoveredThe 1000% batting avg Skier59 was referring to was for the NMIBC Ph. 1b.  

Since the optimized procedure, p#5 and p#6 are both cancer free in 1 single one-hour treatment.  Not bad, isn't it?

Are you also focused, just like BionicBlowJob, on the past?  
Do you think that we're all here for the TLC-2000 or for the oncology division? lolll

By the way, the TLC-2000 re-design is still on the agenda, as per the latest MD&A.  And the COLD Laser therapy will allow them to pre-treat cancer patients, as per the 2 press release of Nov. 27 and Nov. 30 2017, to reverse the Warburg effect.  There's even an upcoming presentation on this:

Photobiomodulation inhibits Warburg metabolism and potentiates a dose dependent response by glioblastoma cells to ruthenium-based photodynamic therapy 
Paper 11070-353
Time: 4:30 PM - 6:30 PM 
Author(s): Mark Roufaiel, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada); Lothar D. Lilge, Univ. of Toronto (Canada), Univ. Health Network (Canada) 
Hide Abstract 
Cancer cells reprogram their metabolism to promote tumorigenesis and increase drug resistance, through the Warburg Effect. The impact of PBM on the Warburg Effect and antineoplastic treatment such as PDT in glioblastoma cells was investigated. Dose dependent PBM mediated decreased glycolysis, increased oxidative phosphorylation, altered cellular proliferation rate, and induced a biphasic response in mRNA expression of multiple cancer genetic markers. These changes are reflected in the efficacy of antineoplastic therapies, here TLD1433-mediated PDT, whereby the efficacy changes also showed a biphasic response, which was not affected by CCO and ROS inhibition, suggesting a CCO and ROS independent mechanism.
Bullboard Posts